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OBJECTIVE—Hemoglobin A1c (A1C) has emerged as a recommended diagnostic tool for
identifying diabetes and subjects at risk for the disease. This recommendation is based on data
in adults showing the relationship between A1C with future development of diabetes and mi-
crovascular complications. However, studies in the pediatric population are lacking.
RESEARCH DESIGN AND METHODS—We studied a multiethnic cohort of 1,156
obese children and adolescents without a diagnosis of diabetes (male, 40%/female, 60%). All
subjects underwent an oral glucose tolerance test (OGTT) and A1C measurement. These tests
were repeated after a follow-up time of ;2 years in 218 subjects.
RESULTS—Atbaseline,subjectswerestratiﬁedaccordingtoA1Ccategories:77%withnormal
glucose tolerance(A1C,5.7%),21% at riskfor diabetes (A1C 5.7–6.4%),and 1% with diabetes
(A1C .6.5%). In the at risk for diabetes category, 47% were classiﬁed with prediabetes or
diabetes, and in the diabetes category, 62% were classiﬁed with type 2 diabetes by the OGTT.
TheareaunderthecurvereceiveroperatingcharacteristicforA1Cwas0.81(95%CI0.70–0.92).
Thethresholdforidentifyingtype2diabeteswas5.8%,with78%speciﬁcityand68%sensitivity.
In the subgroup with repeated measures, a multivariate analysis showed that the strongest
predictors of 2-h glucose at follow-up were baseline A1C and 2-h glucose, independently of
age, ethnicity, sex, fasting glucose, and follow-up time.
CONCLUSIONS—TheAmericanDiabetesAssociationsuggestedthatanA1Cof6.5%under-
estimatestheprevalenceofprediabetesanddiabetesinobesechildrenandadolescents.Giventhe
low sensitivity and speciﬁcity, the use of A1C by itself represents a poor diagnostic tool for
prediabetes and type 2 diabetes in obese children and adolescents.
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A
fter years of debate, the American
Diabetes Association (ADA) pub-
lished revised recommendations to
use hemoglobin A1c (A1C) to diagnose
diabetes and to identify subjects at risk
for developing diabetes in the future (1).
The decisionisbasedonnumerouscross-
sectional and longitudinal studies showing
the correlation between A1C and diabetes
at baseline or long-term association
between A1C and risk of diabetes and
diabetes-related comorbidities (1–6). Ad-
ditional factors inﬂuencing this decision
were as follows: A1C does not require
a fasting state, reﬂects the usual 3–4
months before glycemia, has low intrain-
dividual variability, and is a good predic-
tor of diabetes-related complications
(1,5).Itshouldbenotedthatthisdecision
was made only on studies performed in
adults.Littleisknownabouttheuseofthe
A1C test for the diagnosis of type 2 dia-
betes and prediabetes in childhood and
adolescence. In view of the fact that
both prediabetes and, more important,
type 2 diabetes have recently emerged as
early complications of childhood obesity
(7), it is of critical importance to diagnose
these forms of dysglycemia early in their
development. Thus, the aim of this study
was to assess the diagnostic utility of A1C
forthediagnosisofprediabetesandtype2
diabetes in obese children and adoles-
cents. We therefore conducted this study
to evaluate the following: 1) the distribu-
tion of A1C levels in a multiethnic cohort
ofobesechildrenandadolescentswithout
known diabetes and 2) the sensitivity and
speciﬁcity of A1C for type 2 diabetes and
prediabetes diagnoses compared with
the current oral glucose tolerance test
(OGTT) gold standard.
RESEARCH DESIGN AND
METHODS
Subjects
The Yale Pathophysiology of Type 2 Di-
abetes inObeseYouthStudyisalong-term
project that examines early alterations
in glucose metabolism in obese children
and adolescents. The subjects reported
were recruited from our Pediatric Obe-
sity Clinic from 2005 to 2010. To be
eligible for the study, subjects had to be
obese(.95thpercentileforageandsex)
and were excluded from this analysis
if they were using medications that may
affect glucose metabolism or had known
type 2 diabetes. Children and adolescents
whohadpreviouslyshownfastingglucose
or2-hglucoseindicativeoftype2diabetes
were considered not eligible for the study.
Type 2 diabetes was deﬁned by glucose
levels (fasting glucose .125 mg/dL or
2-h glucose $200 mg/dL) obtained dur-
ing the OGTT (1). Type 1 diabetes was
excluded by testing for GAD 65, islet cell
antibody (ICA) 512, and IA. The obese
children and adolescents of the current
study are referred to the Yale PediatricObe-
sityClinicbylocalcommunitypediatricians
intheareaofNewHaven,Connecticut.The
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ORIGINAL ARTICLEstudy protocol was approved by the insti-
tutional review board of the Yale University
School of Medicine, and written parental
consent and child assent were obtained be-
fore the study.
Testing procedures
Subjects were studied at the research unit at
the Yale University School of Medicine at
8:00 A.M., after a 10-h overnight fast. A stan-
dardoralOGTTadministeringadoseof1.75g
of glucose per kilogram of body weight (up to
a maximum of 75 g) was performed in all
subjectstoestablishglucosetolerancestatus,
as previously described (7). The following
categories of dysglycemia were considered
accordingtoADAdeﬁnition(1):Prediabetes
is consideredwhen an individual shows im-
paired fasting glucose (IFG) (fasting plasma
glucose 100–125 mg/dL) or impaired glu-
cose tolerance (IGT) (2-h glucose after the
OGTT 140–199 mg/dL) or both; type 2 di-
abetes was deﬁned as fasting glucose .125
mg/dL or 2-h glucose $200 mg/dL (1).
Biochemical analyses
Plasma glucose was determined using the
YSI 2700 Stat Analyzer (Yellow Springs
Instruments, Yellow Springs, OH). Fast-
ing plasma insulin was measured using
radioimmunoassays (Linco Research,
St.Charles,MO),andlipidlevelsweremea-
sured with the use of an Auto-Analyzer
(model 747–200, Roche–Hitachi, Indian-
apolis, IN). A1C levels were measured on
the same day of the OGTT by the Yale
Central Laboratory by using an assay
based on latex immunoagglutination in-
hibition methodology (DCA Analyzers,
Siemens, Berlin, Germany).
Calculations. To determine the relation-
ships between categories of A1C and
phenotypes of relevance to the pathogen-
esis of type 2 diabetes, we calculated the
following estimates of both insulin sensi-
tivity and b-cell function during the
OGTT as previously reported:
1. The whole body insulin sensitivity
index (WBISI) is a surrogate measure
of insulin sensitivity, which we have
described and validated against the
euglycemic–hyperinsulinemic clamp
in obese children and adolescents (8).
2. The insulinogenic index (IGI) repre-
sents early-phase insulin secretion and
is a commonly used surrogate index of
b-cell function, as previously reported
(9).
3. The disposition index (DI), which repre-
sents a measure of the insulin secretion
adjusted for the insulin sensitivity, was
calculated as the product of the IGI and
WBISI, based on the curvilinear relation
of these OGTT-derived variables, pre-
viously described by our group in obese
children and adolescents.
Statistical analysis
The study population was described us-
ing mean/SD or frequency. Group com-
parisons across threeA1Ccategorieswere
made with ANOVA. Either raw mean/SD
or least-squares means and 95% CI were
estimated, as well as P value testing for
lineartrendafteradjustingforsex,ethnic-
ities (Caucasian, African American, and
Hispanic), age, and BMI z score if appli-
cable. Because the three ethnic groups
tend to have a different prevalence of pre-
diabetes and type 2 diabetes (7), we ad-
justed for fasting and 2-h glucose.
Geometric means were presented for var-
iables that were log transformed to meet
thenormalassumptionsforanalysis. Glu-
cosetolerance status withineach category
of A1C was examined, and frequency and
percentage were calculated. Agreement
between A1C category and OGTT status
according to fasting glucose or 2-h glu-
cose was also assessed. k and weighted
k coefﬁcient were reported. Receiver op-
erating characteristic (ROC) curve analy-
sis was performed for A1C and fasting
glucose to discriminate IGT from normal
glucose tolerance (NGT) and type 2 dia-
betes from NGT and IGT using a logistic
procedure. Area under the ROC curve
(AUC) was considered as an effective
measure of inherent validity of a diagnos-
tic test. Sensitivity was the percentage of
all patients with type 2 diabetes who are
correctly identiﬁed by different cutoffs of
A1Corfastingglucose.Speciﬁcitywasthe
percentage of all patients without type 2
diabetes who are correctly identiﬁed as
being free of the conditions by different
cutoffs of A1C or fasting glucose. The
ROC curve displayed the trade-off be-
tween the sensitivity and (1- speciﬁcity)
across all observed cutoffs of A1C and
fasting glucose. Then the optimal thresh-
olds for A1C and fasting glucose that
maximized sensitivity + speciﬁcity were
identiﬁed, and corresponding sensitivity
and speciﬁcity were presented. Two
AUCs, for A1C and for fasting glucose,
were compared using Mann-Whitney U
statistic. Multivariate regression was con-
ducted to evaluate the independent effect
of baseline A1C on type 2 diabetes/predi-
abetes or NGT status at follow-up visit
with the adjustment of potential con-
founders. A Pearson correlation was
used to assess simple correlations. SAS
9.2 was used for the analysis (SAS Insti-
tute, Inc., Cary, NC).
RESULTS
Study cohort
At baseline, we studied a multiethnic
cohort of 1,156 obese children and ado-
lescents (Caucasian 36%/African Ameri-
can 35%/Hispanic 29%, 469 male and
687 female) (Supplementary Table 1).
Their mean age was 13.2 6 2.8 (range
4.8–23.1) years; except for the 23.1-
year-old subject, the oldest subjects
were aged 21 years. The median age of
our population was 13.3 years, and the
mode of the age was 14.7 years. The
mean z score BMI was 2.39 6 0.38.
Of 1,156 subjects, 31 (9 male and 22
female) had type 2 diabetes (10 Cauca-
sians, 15 African Americans, and 6 His-
panics) according to the OGTT criteria.
The mean age of this group was 13.7 6
2.25 years, the mean z score BMI was
2.35 6 0.41, the mean fasting glucose
was 116.1 6 20.2 mg/dL, and the mean
2-h glucose was 230.7 6 29.4 mg/dL.
None of them was positive for GAD 65,
ICA 512, or IA.
The average A1C level in the entire
cohortwas5.4160.42%(4.10–8.00).Of
note, there was a signiﬁcant ethnic differ-
ence in the mean A1C among the three
ethnic groups, with African Americans
showing the highest A1C levels (5.55 6
0.45), Caucasians showing the lowest
A1C levels (5.28 6 0.36), and Hispanics
showing middleA1Clevels(5.3860.38)
(P , 0.001). This ethnic difference per-
sisted even after controlling for fasting
and 2-h glucose levels (P , 0.001).
Therewasamodest,albeitsigniﬁcant,
positive relationship between A1C and
fasting glucose (r = 0.29; P , 0.001), and
between A1C and 2-h glucose (r = 0.32;
P , 0.001).
Baseline characteristics of the study
cohort according to A1C categories
At baseline, we stratiﬁed the population
according to A1C categories based on the
ADA 2009 recommendations: NGT (A1C
,5.7%),atriskfordiabetes(A1C5.7–6.4%),
and type 2 diabetes (.6.5%) (Table 1).
According to this classiﬁcation, 77%
were in the NGT category, 21% were in
the at risk for diabetes category, and only
1% were in the type 2 diabetes category
(A1C .6.5%). Both age and sex distribu-
tion were not different among the three
categories; however, it should be noted
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number of female subjects in the higher
categories of A1C. The ethnic differences
amongtheA1Ccategoriesareparticularly
noteworthy; speciﬁcally, there was a
higher prevalence of African Americans
in the at risk for diabetes and type 2 di-
abetescategories(P,0.0001).Acrossthe
A1C categories, subjects tended to be
heavier in the at risk for diabetes and
type 2 diabetes groups (P = 0.01). More-
over, subjects belonging to these two lat-
ter categories showed higher fasting
glucose, fasting insulin, and 2-h glucose
(P , 0.0001), lower insulin sensitivity
(WBISI) (P , 0.0001), a trend toward
lower ﬁrst-phase insulin secretion (IGI,
P = 0.13), and signiﬁcantly lower DI
(P , 0.0001) than subjects with A1C
,5.7%. Plasma triglyceride levels were
higher in the NGT category compared
with both the prediabetic and type 2 di-
abetes categories (P = 0.004), probably be-
cause of the ethnic difference among the
categories, with a lower prevalence of Afri-
can Americans in the lower A1C group.
Baseline distribution of glucose
tolerance status according to A1C
categories
Table 2 describes the proportion of each
type of glucose tolerance status (NGT,
IGT, IFG, IFG/IGT, and type 2 diabetes,
derived from the OGTT) within catego-
ries of A1Cs. First, although the majority
(72%)ofthesubjectswithanA1C,5.7%
wereclassiﬁedasNGTbytheOGTT,27%
were classiﬁed with prediabetes. Second,
ofthesubjectsintheatriskcategory,47%
of them showed laboratory values indic-
ative of prediabetes or diabetes, whereas
the majority (53%) were NGT. Last, the
majority (62%) of subjects with an A1C
.6.5% were classiﬁed as having type 2
diabetes by the OGTT; however, there
were also 12.5% classiﬁed as NGT and
24% classiﬁed as having prediabetes
(IFG and IGT). Thus, of the 247 subjects
categorized as at risk for diabetes on the
basis of their A1C value, only 103 (47%)
were categorized as being at risk on the
basis of their OGTT, and of the 16
classiﬁed with type 2 diabetes by A1C
categories, only 10 (62%) would be indi-
cated as having diabetes. On the other
hand, of those considered as having
type 2 diabetes by using A1C criteria, 6
of 16 (38%) were missed by the OGTT,
whereas among those in the at risk cate-
gory according to A1C criteria, 144 of
247 (58%) were missed by the OGTT.
In other words, the OGTT missed ap-
proximately half of the subjects who
were considered as at risk for diabetes
or having type 2 diabetes by using the
A1Ccriteria.kandweightedkcoefﬁcient
calculated on the basis of Table 2 were
0.17 (95% CI 0.11–0.23) and 0.20
(0.14–0.26), respectively, which also
indicated a poor agreement between
A1C criteria and OGTT status.
Table 1—Clinical features of the study population according to A1C categories at baseline
,5.7 $5.7 to #6.4 .6.4
(n =8 9 3 ) ( n =2 4 7 ) ( n = 16) P
Anthropometrics
Age (years) 13.2 6 2.84 13.1 6 2.76 13.5 6 2.33 0.81
Sex (M/F) (%) 41/59 42/58 28/72 0.70
Race (Caucasian/African American/Hispanic) (%) 42/29/29 18/54/28 28/56/17 ,0.001
BMI z score 2.38 6 0.38 2.44 6 0.38 2.52 6 0.51 0.01
BMI (kg/m
2)# 35.43 (34.98–35.88) 35.88 (35.03–36.73) 38.98 (35.73–42.23) 0.08
Glucose metabolism
Fasting glucose (mg/dL)* 92.07 (91.52–92.62) 96.83 (95.74–97.94) 106.64 (102.03–111.47) ,0.001
2-h Glucose (mg/dL)* 117.58 (116.05–119.13) 130.94 (127.70–134.26) 188.09 (170.61–207.36) ,0.001
Fasting insulin (mU/L)* 29.10 (28.15–30.08) 33.40 (31.36–35.56) 41.81 (32.77–53.34) ,0.001
WBISI* 1.60 (1.54–1.66) 1.35 (1.26–1.45) 1.06 (0.81–1.39) ,0.001
IGI* 3.73 (3.55–3.92) 3.79 (3.46–4.16) 1.82 (1.28–2.61) 0.13
DI* 5.99 (5.73–6.27) 5.20 (4.77–5.67) 1.60 (1.14–2.25) ,0.001
HbA1c (%)* 5.24 (5.22–5.26) 5.88 (5.84–5.92) 6.79 (6.62–6.97) ,0.001
Lipids
Triglycerides (mg/dL)* 98.17 (94.49–102.01) 86.36 (80.14–93.05) 88.96 (65.41–120.98) 0.0040
Cholesterol (mg/dL)* 156.27 (154.14–158.44) 152.34 (148.31–156.48) 156.36 (141.00–173.38) 0.16
HDL (mg/dL)* 41.25 (40.62–41.90) 42.22 (40.96–43.52) 38.08 (33.76–42.97) 0.57
LDL (mg/dL)* 90.01 (88.18–91.88) 87.16 (83.74–90.72) 91.83 (78.36–107.62) 0.27
MeanandSDarepresentedforage,BMI,andzscore.#Adjustedforage,sex,andethnicity.*Logtransformedandadjustedforage,sex,ethnicity,andBMIzscore,and
shown as geometric means and 95% CI. P values are from x
2 test for nominal variables or testing for linear trend for continuous variables across A1C categories.
Table 2—Baseline glucose tolerance according to the A1C categories and OGTT
A1C categories
Total OGTT
,5.7%
(NGT)
5.7–6.4%
(at risk for diabetes)
.6.4%
(type 2 diabetes)
NGT 644 132 2 778
Prediabetes 240 103 4 347
Type 2 diabetes 9 12 10 31
Total 893 247 16 1,156
k coefﬁcient 0.17 with 95% CI (0.11–0.23); weighted k 0.20 with 95% CI (0.14–0.26).
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HbA1c and prediabetes/diabetes in childhoodComparisons between A1C and
fasting glucose: AUC analysis
at baseline
The AUCs shown in Fig. 1A and B repre-
sent the diagnostic accuracy of the A1C,
compared with fasting glucose, for IGT
and type 2 diabetes, respectively. For
IGT, the AUC for A1C was 0.60 (95%
CI 0.56–0.65) and the AUC for fasting
glucose was 0.67 (0.63–0.72) (Fig. 1A).
The optimal threshold of A1C was 5.5%,
with a speciﬁcity of 59.9% and sensitivity
of 57.0%. The two areas differed signiﬁ-
cantly from each other (P = 0.01). In con-
trast, in the type 2 diabetes category, the
diagnostic accuracy of A1C and fasting
glucose was not signiﬁcantly different
(P = 0.13). The AUC for A1C was 0.81
(0.70–0.92), and the AUC fasting glucose
was 0.89 (0.82–0.97) (Fig. 1B). The opti-
mal threshold of A1C was 5.8% in iden-
tifying type 2 diabetes, with a speciﬁcity
of 87.64% and sensitivity of 67.7%.
Follow-up data
To test the predictive value of A1C to
diagnose prediabetes and type 2 diabetes,
we analyzed data from 218 subjects on
whom we had repeated measures after a
meanof1.6860.92years.Thefollow-up
group did not differ from the subjects lost
to follow-up in terms of ethnicity (Cauca-
sian 41.5%/African American 30.2%/
Hispanic28.3%,P=0.2),sexdistribution
(male 36.3%, female 63.7%, P = 0.16),
and A1C levels (5.39 6 0.39 vs. 5.41 6
0.42, range 4.3–6.5, P =0 . 3 ) .
At baseline, 139 subjects (63.76%)
had NGT, 26 subjects (6.88%) had IFG
only, 23 subjects (10.55%) had IGT only,
26 subjects (11.92%) had IGT and IFG,
and 4 subjects (1.83%) had type 2 di-
abetes. Subjects in the follow-up group
tended to be younger (mean age 12.53 6
2.83 years, range 5.8–21; P = 0.001) than
those who did not come to follow-up
visits (mean age 13.36 6 2.8 years, range
4.8–23.1).
Baseline and follow-up A1C were
highly correlated (r = 0.78, P , 0.0001).
The correlation between baseline A1C
and follow-up fasting and 2-h glucose
(r = 0.33; P , 0.0001 and r = 0.32; P ,
0.0001, respectively) were similar to
those observed in the whole population
at baseline. A multivariate analysis
showed that the strongest predictors of
2-h glucose at follow-up were baseline
A1C and baseline 2-h glucose levels
(P = 0.001 and P , 0.0001, respectively)
independentlyofage,ethnicity,sex,base-
line fasting glucose, changes in BMI z
score, and follow-up time. Baseline A1C
strongly predicted follow-up prediabetes/
diabetes; the results from multivariate
analysis showed a 1% increase in baseline
A1C corresponding to 13-fold (95% CI
4.79–36.88) increases in the likelihood
of having prediabetes/diabetes at follow-
up, after adjusting for age, sex, race, and
follow-up time. After additionaladjusting
for baseline fasting glucose and 2-h glu-
cose, the strong effect of A1C still existed
(odds ratio 6.6 [2.27–19.24]). Subjects
with a baseline A1C $5.7 had a greater
chance (odds ratio 5.7 [CI 1.54–10.31])
of having prediabetes/diabetes at the
follow-up visit than their peers with a
lower A1C (,5.7) at baseline, after con-
trollingforage,sex,ethnicity,andfollow-
up time.
CONCLUSIONS—In a large clinic-
based multiethnic cohort of obese children
and adolescents, regardless of age and sex,
an A1C of 6.5% had relatively low sensi-
tivity and speciﬁcity for classifying type 2
diabetes. There was poor agreement be-
tweenA1CandOGTTcriteriainclassifying
subjects with glucose values suggestive of
type 2 diabetes. The optimal threshold of
A1C was 5.8% for identifying type 2 di-
abetes, with a speciﬁcity of 87.64% and
Figure1—ComparisonbetweentheAUCsoftheA1CandfastingglucoseforIGT(A)andtype2diabetes(B)atbaseline.Thereddiscontinuousline
indicatesthecurvedeﬁningtheareafortheA1C,andthebluecontinuouscurvedeﬁnestheareaforfastingglucose.Thevalueofeachareaisspeciﬁed
next to the two variables (A1C and fasting glucose) at the bottom of the ﬁgure.
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fying IGT. The diagnostic utility of A1C
wasexaminedaccordingtoADAcriteria(1)
with OGTT as the reference. We observed
that the use of an A1C of 6.5% would
largely underestimate the prevalence of
prediabetes and type 2 diabetes. Our re-
sults suggest that, although A1C could be
used as a clinical tool to identify type 2 di-
abetes, along with fasting and 2-h glucose,
the use of A1C by itself to pinpoint predi-
abetes and type 2 diabetes is not recom-
mended. Our data are in agreement with
those who reported using the National
Health and Nutrition Examination Survey
of 14,611 individuals aged $20 years,
clearly showing that an A1C of 6.5%
has a lower capacity to detect prediabetes
and undiagnosed type 2 diabetes than the
OGTT (10).
Studies in adults have clearly shown
the utility of A1C in predicting type 2
diabetes (11–14) and cardiovascular dis-
ease even in nondiabetic adults (6). Nev-
ertheless, concerns in the use of A1C for
diagnosing type 2 diabetes have been re-
cently raised (15) in view of the poor re-
lationship with fasting glucose (16), the
overall lower diagnostic performance in
some groups such as pregnant women
and elderly, and the risk of overdiagnos-
ing patients with anemia and those pre-
disposed to rapid glycosylation (15). In
addition, as previously stated (10), it
should be noted that, despite the numer-
ous advantages, the use of A1C as a diag-
nostic tool would largely affect national
surveillance of prediabetes and type 2 di-
abetes.
Different cutoff points have been
reported when the ROC curve was used
to identify the cutoff point for diagnosing
type 2 diabetes or prediabetes (11). A re-
view on A1C as a screening tool for dia-
betes (11) showed that three cutoff points
(5.9, 6.1, and 6.3%) of A1C were advised
ascutoffpointsfordetectingdiabetesinat
least twodifferent studies,andmoststud-
ies identiﬁed a cutoff point of $6.1% as
optimum for the detection of type 2 di-
abetes. In addition, the authors con-
cluded that at equivalent cutoff points,
sensitivity was generally lower in detect-
ing IGT for both A1C and fasting plasma
glucose in both community- and hospi-
tal-based studies (11). Thus, the cutoff
point identiﬁed in our study of 5.8% is
somewhat lower than oftentimes repor-
ted, which might indicate that our popu-
lation is of especially high risk.
Although only a small percentage of
subjects had a repeated A1C and OGTT
after a follow-up of 2 years, we believe
that the data are important, indicating
that the best predictors of future diabetes
or prediabetes are A1C and the 2-h
glucose from the OGTT. Thus, both the
cross-sectional and longitudinal data
would argue in favor of the utility of
performing both tests in obese youth
for predicting future development of
diabetes.
Ethnic disparities in A1C in adults
have been suggested by others (17). Al-
though previous studies attributed ethnic
differences in A1C to a poorer glycemic
control among ethnic minorities (18),
studies in nondiabetic subjects showed
that these differences are not related, or
at least not only related, to the different
glycemic control (19–21). Other studies
have clearly shown that factors inﬂuenc-
ing glycemia, such as adiposity, fasting,
postglucose load glucose levels, b-cell
function, and insulin resistance, do not
explain ethnic differences in A1C.
It is known that conditions charac-
terized by altered erythrocyte physiology
may inﬂuence the utility of A1C in di-
abetesdiagnosis(22).Recentlyithasbeen
shown that some common genetic varia-
tions resulting in alterations in iron levels
or hemoglobin concentration can also af-
fect A1C levels (23).
A few limitations are worth noting.
There is no lean control group, a clinic-
based cohort was studied, and the follow-
up group is small. Strengths include the
large group of obese youngsters without
known diabetes and the existence of data
derived on the same day for both the
OGTT and A1C.
In conclusion, the use of A1C alone
may result in missed or delayed individ-
uation of prediabetes/type 2 diabetes
given the limited sensitivity of the A1C
test. Further investigation on the role of
A1C in the diagnosis of prediabetes and
diabetes in children and adolescents is
needed. Prospective studies are especially
importanttoexaminetheutilityofA1Cin
pediatric populations in the prediction of
diabetes-related comorbidities later in
life.
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